Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 dupilumab study in adult and adolescent eosinophilic esophagitis
NL-OMON55352Phase 3Active, not recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jan 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of dupilumab in eosinophilic esophagitis (EoE), sponsored by Regeneron Pharmaceuticals. Started Jan 2020; status: active, not recruiting.
02
Drugs
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on NL-OMON55352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55352.